Soligenix, Inc.

NasdaqCM:SNGX 주식 보고서

시가총액: US$8.6m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Soligenix 관리

관리 기준 확인 4/4

Soligenix's CEO는 Christopher Schaber, Aug2006 에 임명되었습니다 의 임기는 18.08 년입니다. 총 연간 보상은 $ 700.49K, 74.2% 로 구성됩니다. 74.2% 급여 및 25.8% 보너스(회사 주식 및 옵션 포함). 는 $ 1.33K 가치에 해당하는 회사 주식의 0.017% 직접 소유합니다. 1.33K. 경영진과 이사회의 평균 재임 기간은 각각 10.2 년과 15.2 년입니다.

주요 정보

Christopher Schaber

최고 경영자

US$700.5k

총 보상

CEO 급여 비율74.2%
CEO 임기18.1yrs
CEO 소유권0.02%
경영진 평균 재임 기간10.2yrs
이사회 평균 재임 기간15.2yrs

최근 관리 업데이트

Recent updates

Soligenix: A Biotech Bargain Ready To File For Approval In Cutaneous T-Cell Lymphoma

Oct 05

U.S. FDA awards $2.6M grant for expanded study of Soligenix's HyBryte for skin cancer

Sep 12

Soligenix announces $2.6M FDA grant to further study blood cancer candidate

Sep 06

Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?

Sep 06
Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?

Soligenix GAAP EPS of -$0.06 beats by $0.03, revenue of $0.4M beats by $0.2M

Aug 12

Soligenix, SERB Pharma team up to develop therapy for ricin poisoning

Jul 25

Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?

Apr 22
Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?

Is Soligenix (NASDAQ:SNGX) Using Too Much Debt?

Jan 03
Is Soligenix (NASDAQ:SNGX) Using Too Much Debt?

Shareholders May Find It Hard To Justify Increasing Soligenix, Inc.'s (NASDAQ:SNGX) CEO Compensation For Now

Sep 17
Shareholders May Find It Hard To Justify Increasing Soligenix, Inc.'s (NASDAQ:SNGX) CEO Compensation For Now

Health Check: How Prudently Does Soligenix (NASDAQ:SNGX) Use Debt?

Aug 30
Health Check: How Prudently Does Soligenix (NASDAQ:SNGX) Use Debt?

Is Soligenix (NASDAQ:SNGX) Weighed On By Its Debt Load?

May 08
Is Soligenix (NASDAQ:SNGX) Weighed On By Its Debt Load?

What Type Of Returns Would Soligenix's(NASDAQ:SNGX) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Mar 16
What Type Of Returns Would Soligenix's(NASDAQ:SNGX) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Soligenix inks supply and distribution deal for SGX301 companion light device in cancer

Jan 07

Soligenix receives $1.5M grant advancing COVID-19 vaccine development

Dec 28

CEO 보상 분석

Christopher Schaber 의 보수는 Soligenix 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Jun 30 2024n/an/a

-US$7m

Mar 31 2024n/an/a

-US$7m

Dec 31 2023US$700kUS$519k

-US$6m

Sep 30 2023n/an/a

-US$8m

Jun 30 2023n/an/a

-US$10m

Mar 31 2023n/an/a

-US$10m

Dec 31 2022US$711kUS$499k

-US$14m

Sep 30 2022n/an/a

-US$15m

Jun 30 2022n/an/a

-US$15m

Mar 31 2022n/an/a

-US$15m

Dec 31 2021US$687kUS$485k

-US$13m

Sep 30 2021n/an/a

-US$13m

Jun 30 2021n/an/a

-US$12m

Mar 31 2021n/an/a

-US$12m

Dec 31 2020US$944kUS$475k

-US$18m

Sep 30 2020n/an/a

-US$15m

Jun 30 2020n/an/a

-US$16m

Mar 31 2020n/an/a

-US$15m

Dec 31 2019US$688kUS$466k

-US$9m

Sep 30 2019n/an/a

-US$10m

Jun 30 2019n/an/a

-US$9m

Mar 31 2019n/an/a

-US$8m

Dec 31 2018US$619kUS$453k

-US$9m

Sep 30 2018n/an/a

-US$8m

Jun 30 2018n/an/a

-US$7m

Mar 31 2018n/an/a

-US$8m

Dec 31 2017US$674kUS$444k

-US$7m

보상 대 시장: Christopher 의 총 보상 ($USD 700.49K )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 679.82K ).

보상과 수익: Christopher 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Christopher Schaber (58 yo)

18.1yrs

테뉴어

US$700,485

보상

Dr. Christopher J. Schaber, Ph D., has been the President and Chief Executive Officer at Soligenix, Inc. since August 30, 2006. Dr. Schaber has broad experience in the pharmaceutical and biotechnology indu...

리더십 팀

이름위치테뉴어보상소유권
Christopher Schaber
Chairman of the Board of Directors18.1yrsUS$700.49k0.017%
$ 1.4k
Jonathan Guarino
Senior VP5yrsUS$354.69k0.0020%
$ 173.2
Oreola Donini
Senior VP & Chief Scientific Officer9.8yrsUS$387.59k0%
$ 0
Richard Straube
Senior VP & Chief Medical Officer10.7yrsUS$249.94k0.0015%
$ 127.8

10.2yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 관리: SNGX 의 관리팀은 노련하고 경험 (평균 재직 기간 10 년)입니다.

이사회 구성원

이름위치테뉴어보상소유권
Christopher Schaber
Chairman of the Board of Directors18.1yrsUS$700.49k0.017%
$ 1.4k
Jerome Zeldis
Independent Director13.3yrsUS$72.50k0.0042%
$ 361.0
Gregory Lapointe
Independent Director15.5yrsUS$77.50k0.0014%
$ 116.6
Robert Rubin
Independent Director14.9yrsUS$80.00k0.00083%
$ 71.2
Dorothy Mary Keefe
Member of Oral Mucositis Medical Advisory Boardno data데이터 없음데이터 없음
Jeffrey Hyams
Member of Pediatric Crohn's Disease Medical Advisory Boardno data데이터 없음데이터 없음
James Markowitz
Member of Pediatric Crohn's Disease Medical Advisory Boardno data데이터 없음데이터 없음
Joel Rosh
Member of Pediatric Crohn's Disease Medical Advisory Boardno data데이터 없음데이터 없음
Alain Rook
Member of Cutaneous T-Cell Lymphoma Medical Advisory Boardno data데이터 없음데이터 없음
Mark Schubert
Member of Oral Mucositis Medical Advisory Boardno data데이터 없음데이터 없음
Youn Kim
Member of Cutaneous T-Cell Lymphoma Medical Advisory Boardno data데이터 없음데이터 없음
Gary Wood
Member of Cutaneous T-Cell Lymphoma Medical Advisory Boardno data데이터 없음데이터 없음

15.2yrs

평균 재임 기간

69.5yo

평균 연령

경험이 풍부한 이사회: SNGX 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 15 년).